🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Bristol Myers earnings beat expectations, driven by sales of older drugs

Published 10/31/2024, 07:19 AM
Updated 10/31/2024, 11:56 AM
© Reuters. FILE PHOTO: A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S., July 22, 2022.  REUTERS/George Frey/File Photo
BMY
-

By Michael Erman

(Reuters) -Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid as well as newer products such as heart medicine Camzyos and cancer cell therapy Breyanzi.

Shares were up 4.2% after earlier climbing to $56.20, their highest level since last October.

The U.S. drugmaker said it earned $3.7 billion in the quarter, or $1.80 per share, compared with $4.1 billion, or $2 per share, a year earlier. Analysts, on average, expected the company to earn $1.49 in the quarter, according to LSEG data.

Revenue rose 8% to $11.89 billion, exceeding analysts' forecasts of $11.28 billion.

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, but topped analyst expectations of $1.11 billion. Sales of Eliquis, which Bristol Myers (NYSE:BMY) shares with Pfizer (NYSE:PFE), rose 11% in the quarter to $3 billion, compared with analyst estimates of $2.83 billion.

"The legacy portfolio has continued to contribute a significant amount of cash flow to the company, and that's enabled us to deleverage and strengthen the balance sheet," Chief Financial Officer David Elkins said in an interview.

"But the majority of the growth of the company overall ... was really driven by the growth portfolio growing 20% versus prior year," Elkins said.

Sales of Breyanzi and Camzyos more than doubled year-over-year. Breyanzi sales for the quarter were $224 million, while Camzyos brought in $156 million.

"As generic competition and IRA (Inflation Reduction Act) loom, investors need more from growth assets and Cobenfy," said Guggenheim Securities analyst Seamus Fernandez, referring to Bristol's recently approved schizophrenia drug.

Eliquis was one of the 10 drugs included in the first wave of Medicare price negotiations allowed under the IRA and faces a price cut of 56% beginning in 2026.

Fernandez said the modest beat for products like Camzyos and Breyanzi was encouraging, but was not a source of enthusiasm.

The company is awaiting U.S. approval of an under-the-skin injection form its cancer drug Opdivo, expected by the end of 2024. The original intravenous form of the cancer immunotherapy is expected to lose patent protection later this decade.

© Reuters. FILE PHOTO: A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S., July 22, 2022.  REUTERS/George Frey/File Photo

"We anticipate this launch in early 2025 will provide an important benefit for both patients and physicians," said CEO Chris Boerner on a call to discuss financial results.

Bristol Myers raised its full-year earnings forecast to 75 cents to 95 cents a share, from 60 cents to 90 cents previously. Analysts had forecast full-year earnings of around 71 cents a share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.